坎地沙坦西酯治疗轻、中度高血压的临床观察

Clinical Observation on Candesartan in Treating Mild-to-Moderate Hypertension

目的 评价坎地沙坦西酯 (candesartan ,CAN)治疗轻、中度高血压病 (EH)的临床疗效和安全性。方法 选原发性轻、中度EH患者 38例 [坐位舒张压 (SiDBP) 90～ 1 1 0mmHg] ,随机双盲给药 ,其中 1 8例服用CAN 8mg/d,1 8例服用氯沙坦 (Losartan,LOS) 50mg/d ,于 4周末SiDBP≥ 90mmHg者剂量增加至CAN 1 6mg/d或LOS 1 0 0mg/d ,总疗程 8周。结果 双盲对照组 8周末有效率 :CAN组 77.8% ,LOS组 72 .2 % ,组间比较差异无显著性 (P >0 .0 5)。 8周末CAN组SiSBP/SiDBP下降 (2 0 .1 5± 1 3 .1 3/1 0 .92± 3 .1 8)mmHg ,LOS组下降 (1 9.2 1± 1 1 .61 /9.74± 1 6 .2 1 )mmHg。 2、4、6、8周末血压下降值 ,组间比较差异无显著性 (P >0 .0 5)。CAN组降压疗效随剂量增加而增加 ,与LOS组比较增加剂量疗效差异有显著性。两药不良反应发生率低 ,差异无显著性。结论 CAN 8～ 1 6mg/d治疗轻、中度EH疗效确切 ,耐受性好 。

Objective To evaluate the efficacy and safety of candesartan(CAN) in treating essential hypertension. Methods Patients with mild to moderate essential hypertension sitting diastolic blood pressure(SiDBP) of 90～110 mmHg (1mmHg=0.133kPa) were recruited. The double-blind and randomization were adopted, the patients were administered CAN(n=18)8mg/day or Losartan(LOS)(n=18) 50mg/day for 4 weeks, followed by dose increase to CAN 16mg/day or LOS 100mg/day for another 4 weeks in those patients with SiDBP≥90mmHg.Results At the end of 8 weeks, no statistical difference was found between the effective rates of CAN and LOS (77.8% vs 72.2%,P>0.05).SiSBP/SiDBP was decreased by (20.15±13.13/10.92±3.18)mmHg by CAN and (19.21±11.61/9.74±16.21)mmHg by LOS. The decrease in blood pressure showed no difference between the two groups at the end of 2,4,6 and 8 weeks (P>0.05). The efficacy of the decrease in blood pressure in CAN group was significantly better than that in LOS group. The rate of adverse reaction was very low and showed no difference between two kinds.Conclusion CAN 8～16 mg/day is effective and well tolerated with mild to moderate essential hypertension without the adverse reaction.